Ianalumab reduces Sjögren disease activity
Sarah Onuora
Nature Reviews Rheumatology
· Springer Nature
· 2026-11-10
· DOI: 10.1038/s41584-026-01466-3
Abstract
Nature Reviews Rheumatology, Published online: 10 November 2026; doi:10.1038/s41584-026-01466-3 In patients with active Sjögren disease, treatment with ianalumab 300 mg monthly reduced disease activity, but not symptom scores, more than placebo in two phase III clinical trials.
Read at publisher →
Cite
Get new articles on “Rheumatology”
Subscriptions, keyword tracking and favourites — in the Articlium Telegram bot.
Open in Telegram
Citation
✕
ГОСТ
APA
MLA
BibTeX
Sarah Onuora. Ianalumab reduces Sjögren disease activity. // Nature Reviews Rheumatology. – 2026. – DOI: 10.1038/s41584-026-01466-3. – URL: https://www.nature.com/articles/s41584-026-01466-3
Sarah Onuora (2026). Ianalumab reduces Sjögren disease activity. Nature Reviews Rheumatology. https://doi.org/10.1038/s41584-026-01466-3
Sarah Onuora. “Ianalumab reduces Sjögren disease activity.” Nature Reviews Rheumatology, 2026. doi:10.1038/s41584-026-01466-3.
@article{Onuora2026,
title = {Ianalumab reduces Sjögren disease activity},
author = {Onuora, Sarah},
journal = {Nature Reviews Rheumatology},
year = {2026},
doi = {10.1038/s41584-026-01466-3},
url = {https://www.nature.com/articles/s41584-026-01466-3}
}